AurimMed Pharma is an applied-science, development-stage pharmaceutical company. AurimMed is developing small-molecule pharmaceutical products by using carefully selected privileged structures as lead compounds for proprietary product development. This rational, proven strategy greatly shortens product development times while enhancing clinical and commercial success.
The company is currently developing compounds active in the Central Nervous System (CNS) such as novel anticonvulsants, analgesics (for neuropathic pain), and neuroprotective agents. Such CNS-active agents are also often useful in the treatment of anxiety, depression, insomnia, schizophrenia, Parkinson’s disease, and bipolar disorder.
The initial focus of AurimMed Pharma is the development of safe and effective drug products up through Phase I clinical trials. Upon completion of the initial trials, the Company intends to seek agreements with larger biopharmaceutical and/or large pharmaceutical companies in order to co-develop the products through Phase II/III clinical trials. Alternatively, the company would consider licensing the products to companies with existing marketing and business development infrastructure for the marketing of drug products.